Sanofi backed by big pharma and more in SCOTUS clash
Case focuses on the enablement scope of patents | Amici curiae argue Amgen patents are too broad | Pfizer | Eli Lilly | AstraZeneca | Sanofi | Genentech | Bayer | Gilead Sciences| Johnson & Johnson.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
18 May 2023 Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.
28 March 2023 As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
15 December 2022 As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.